Short answer
Enliven Therapeutics, Inc. (ELVN) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 financial results for quarter ended March 31, 2026.
Enliven Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release issued May 7, 2026 and filed as Exhibit 99.1
- Exhibit 99.1 contains the substantive financial results and management disclosures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Enliven Therapeutics, Inc. 8-K filings
Get the next ELVN 8-K as it lands
Follow ELVN for push alerts, or ask the research agent what this filing means.